Sten Nilsson

14.8k total citations · 1 hit paper
263 papers, 7.8k citations indexed

About

Sten Nilsson is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Sten Nilsson has authored 263 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 150 papers in Pulmonary and Respiratory Medicine, 105 papers in Radiology, Nuclear Medicine and Imaging and 74 papers in Oncology. Recurrent topics in Sten Nilsson's work include Prostate Cancer Treatment and Research (116 papers), Radiopharmaceutical Chemistry and Applications (88 papers) and Prostate Cancer Diagnosis and Treatment (47 papers). Sten Nilsson is often cited by papers focused on Prostate Cancer Treatment and Research (116 papers), Radiopharmaceutical Chemistry and Applications (88 papers) and Prostate Cancer Diagnosis and Treatment (47 papers). Sten Nilsson collaborates with scholars based in Sweden, United States and United Kingdom. Sten Nilsson's co-authors include Øyvind S. Bruland, Per A. Peterson, Roy H. Larsen, Joe M. O’Sullivan, Oliver Sartor, Jan‐Erik Westlin, Per‐Uno Malmström, Nicholas J. Vogelzang, Bo Lennernäs and Erkki Rintala and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

Sten Nilsson

257 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

2014 290 citations Peter Hoskin, Oliver Sartor et al. profile →

Peers

Countries citing papers authored by Sten Nilsson

Since Specialization

Citations

This map shows the geographic impact of Sten Nilsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sten Nilsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sten Nilsson more than expected).

Fields of papers citing papers by Sten Nilsson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sten Nilsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sten Nilsson. The network helps show where Sten Nilsson may publish in the future.

Co-authorship network of co-authors of Sten Nilsson

This figure shows the co-authorship network connecting the top 25 collaborators of Sten Nilsson. A scholar is included among the top collaborators of Sten Nilsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sten Nilsson. Sten Nilsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial 2016 ·European Urology ·Christopher Parker, Steven E. Finkelstein, Jeff M. Michalski, Joe M. O’Sullivan, Øyvind S. Bruland, Nicholas J. Vogelzang, Robert E. Coleman, Sten Nilsson, Oliver Sartor, Rui Li, Monica Seger, David Bottomley	51
2	Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP) 2016 ·Annals of Oncology ·Daniel Heinrich, Silke Gillessen, Axel Heidenreich, (unknown), Joe M. O’Sullivan, Joan Carles, M. Wirth, (unknown), Giuseppe Procopio, Jeremy Gratt, (unknown), Sten Nilsson, (unknown)	4
3	Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP) 2016 ·Annals of Oncology ·Fred Saad, Axel Heidenreich, Daniel Heinrich, Daniel Keizman, Joe M. O’Sullivan, Joan Carles, M. Wirth, K. Miller, Jeremy Gratt, (unknown), Sten Nilsson, Silke Gillessen	1
4	An expression signature at diagnosis to estimate prostate cancer patients’ overall survival 2014 ·Prostate Cancer and Prostatic Diseases ·Zheng Peng, Lambert Skoog, Henrik Hellborg, (unknown), (unknown), Marie Hjälm-Eriksson, Ulrika Harmenberg, (unknown), Karl Andersson, (unknown), Setia Pramana, Yudi Pawitan, Monica Nistér, Sten Nilsson, Chunde Li	33
5	Hematologic Safety Profile of Radium-223 Dichloride (Ra-223) From the Phase 3 ALSYMPCA Trial in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases 2013 ·European Journal of Nuclear Medicine and Molecular Imaging ·Anders Widmark, Svein Inge Helle, Nicola James, (unknown), K. Staudacher, I.K. Haugen, J. Garcia‐Vargas, Sten Nilsson	0
6	Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) and bone metastases 2013 ·European Journal of Cancer ·Chris Parker, Daniel Heinrich, David Bottomley, Peter Hoskin, Lars Franzén, A. Solberg, (unknown), Jonathan Reuning‐Scherer, C. Gillies O'Bryan-Tear, Sten Nilsson	2
7	Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: Single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy 2012 ·International Journal of Oncology ·(unknown), (unknown), (unknown), (unknown), Peter Wiklund, Stefan Carlsson, Gabriella Cohn‐Cedermark, Ulrika Harmenberg, Ove Gustafsson, Seymour H. Levitt, Bo Lennernäs, Yvonne Brandberg, Marcela Márquez, Karl‐Mikael Kälkner, Sten Nilsson	12
8	A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer 2012 ·European Journal of Cancer ·Sten Nilsson, Peter Strang, A. Aksnes, Lars Franzén, Patrick Olivier, A Pecking, J. Staffurth, S. Vasanthan, Charlotte Andersson, Øyvind S. Bruland	191
9	XAF1 expression and regulatory effects of somatostatin on XAF1 in prostate cancer cells 2010 ·Journal of Experimental & Clinical Cancer Research ·Zhaoquan Xing, Zunlin Zhou, Rong Yu, Shuling Li, Chunde Li, Sten Nilsson, Zhaoxu Liu	7
10	Dosimetry of anal radiation in high-dose-rate brachytherapy for prostate cancer 2006 ·Brachytherapy ·Karl Mikael Kälkner, (unknown), (unknown), (unknown), Sten Nilsson, Seymour H. Levitt, Marie Lundell	4
11	Barriers Identified by Swedish School Nurses in Giving Information about Testicular Cancer and Testicular Self-Examination to Adolescent Males 2005 ·The Journal of School Nursing ·(unknown), Sten Nilsson, Karin Wikblad, Marianne Carlsson	1
12	Intention to test for prostate cancer 2005 ·European Journal of Cancer ·Gunilla Berglund, Sten Nilsson, Karin Nordin	25
13	Self-perceived Physical, Psychologic, and General Symptoms in Survivors of Testicular Cancer 3 to 13 Years After Treatment 2002 ·Cancer Nursing ·(unknown), Marianne Carlsson, Sten Nilsson, Karin Wikblad	44
14	The Swedish Council on Technology Assessment in Health Care (SBU) Systematic Overview of Chemotherapy Effects in Some Major Tumour Types - Summary and Conclusions 2001 ·Acta Oncologica ·Ingrid Glimelius, Jonas Bergh, L. Brandt, Bengt Brorsson, Barbro Gunnars, Larsolof Hafström, U Haglund, Thomas Högberg, (unknown), Per‐Ebbe Jönsson, Göran Karlsson, Eva Kimby, (unknown), Sten Nilsson, Johan Permert, Peter Ragnhammar, Sverre Sörenson, Peter Nygren	31
15	Expression of epidermal growth factor receptor in urinary bladder cancer metastases 1998 ·International Journal of Cancer ·(unknown), Kenneth Wester, Anna Sjöström, Anders Holmberg, Sten Nilsson, Jörgen Carlsson, Jan‐Erik Westlin, Christer Busch, Per‐Uno Malmström	1
16	Expression of epidermal growth factor receptor in urinary bladder cancer metastases 1998 ·International Journal of Cancer ·(unknown), Kenneth Wester, (unknown), Anders Holmberg, Sten Nilsson, Jörgen Carlsson, Jan‐Erik Westlin, Christer Busch, Per‐Uno Malmström	41
17	E4, A New Monoclonal Antibody Identifying a Human Prostatic Cell Surface Antigen 1997 ·Cancer Biotherapy and Radiopharmaceuticals ·Sten Nilsson, Magnus Essand, (unknown), (unknown), Hans Nordgren, (unknown)	2
18	Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer 1997 ·European Journal of Cancer ·Olbjørn Klepp, O. Dahl, Per Flodgren, Ulrika Stierner, Arne M. Olsson, J. Oldbring, Sten Nilsson, L Daehlin, Magnus Törnblom, (unknown), Hans Starkhammar, (unknown), E. Wist, Nils Raabe, (unknown), Eva Cavallin‐Ståhl	60
19	The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer 1997 ·British Journal of Haematology ·(unknown), Sten Nilsson, Per Venge	34
20	Immunotargeting with Monoclonal Cytokeratin 8 Antibodies of Human Urothelial Cancer Transplanted to Nude Mice 1993 ·Acta Oncologica ·Henry Letocha, Sten Nilsson, (unknown), Jonas Ekblom, Henrik Arnberg, (unknown), Jan‐Erik Westlin	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact